1. Barelli P.A., Kern E.B., Loch W.E.E., Steiner A. (red.): Rhinology: The Collected Writings of Maurice H. Cottle, M.D. American Rhinologic Society, 1987.

2. Eccles R.: Nasal airflow in health and disease. Acta Otolaryngol 2000, 120: 580–595.

3. Sommer F., Kröger R., Lindemann J.: Numerical simulation of humidification and heating during inspiration within an adult nose. Rhinology 2012, 50: 157–164.

4. SamoliÅ„ski B., Arcimowicz M. (red.): Polskie Standardy Leczenia Nieżytów Nosa (PoSLeNN). Stanowisko Panelu Ekspertów PTA. Alergologia Polska 2013, S1: 1–167.

5. Lindemann J., Keck T., Wiesmiller K. i wsp.: Nasal air temperature and airflow during respiration in numerical simulation based on multislice computed tomography scan. Am J Rhinol 2006, 20: 219–223.

6. Rapiejko P., Paczesny D., Jachowicz R., i wsp.: Temperature and humidity profile in nasal cavity. Pol. J. Environ Studies 2006, 15:665-669.

7. Lund V.J.: International Consensus Report on the Diagnosis and Management of Rhinitis. Allergy 1994, 49: 1-34.

8. Meltzer E., Orgel H., Jalowayski A.: Cytology. w: Myginda N., Naclerio R.M.: Allergic and Non-Allergic Rhinitis - Clinical Aspects. Munksgaard 1993: 66-81.

9. Warner J.O.: Allergic rhinitis is an extremely common problem, but prevalence rates widely vary between countries. Pediatr Allergy Immunol 2010, 21 (1 Pt 2):105–106.

10. SamoliÅ„ski B., Sybilski A.J., Raciborski F. i wsp.: Prevalence of rhinitis in Polish population according to the ECAP (Epidemiology of Allergic Disorders in Poland) study. Otolaryngol Pol 2009, 63: 324–330.

11. European Allergy White Paper. Allergic diseases as a public health problem in Europe. Ed. D. Van Moerbeke. The UCB Institute of Allergy, Brussels 1997.

12. Juniper E.F. i wsp.: Interpretation of rhinoconjunctivitis quality of life questionnaire data. J. Allergy Clin. Immunol. 1996, 98: 843-5.

13. Sibbald B., Rink E.: Labelling of rhinitis and hay fever by doctors. Thorax 1991, 46: 378-81.

14. Weeke E.R.: Epidemiology of allergic diseases in children. Rhinol. 1992, 13 (Suppl.): 5-12.

15. Murry JJ., Tonnel AB., Brash AR., i wsp. Prostaglandin D2 is released during acute allergic bronchospasm in man. Trans Assoc Am Phisicians 1985; 98: 275-328.

16. Tonnel AB, Joseph M, Gosset P. i wsp. Stimulation of alveolar macrophages in asthmatic patients after local provocation test. Lancet 1983; 1: 1406-1408.

17. Samoliński B., Rapiejko P. Odpowiedź wczesna po donosowej próbie prowokacyjnej z alergenem. Postęp Derm. Alergol 2010; 27: 170-172.

18. Pawliczek R. Patofizjologia alergii i astmy. W: Alergia i choroby alergiczne, astma Fal AM (red). Medycyna Praktyczna, Kraków 2010.

19. Lebel B., Bousquet J., Morel A., i wsp. Correlation between symptoms and the threshold for release of mediators in nasal secretions during nasal challenge with grass-pollen grains. J Allergy Clin Immunol 1988; 82: 869-877.

20. Pastorello EA., Riario-Sforza GG., Incorvaia C., i wsp. Comparison of rhinomanometry, symptom score, and inflammatory cell counts in assessing the nasal late-phase reaction to allergen challenge. J Allergy Clin Immunol 1994; 93:85-92.

21. Brozek JL., Bousquet J.,Baena-Cagnani CE., i wsp. Allergic Rhinitis and Ihs on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126: 466-476.

22. Bousquet J., Van Cauwenberge P., Khaltaev N.; Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (5 Suppl); 147-334.

23. Kruszewski J. Diagnostyka alergologiczna. W: Diagnostyka rynologiczna. Krzeski A. (red.). medycyna Praktyczna, Kraków 2009.

24. Bousquet J., Khatlaev N., Cruz A. i wsp.: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the Worl Heath Organization, GA2LEN and Alergen). Allergy 2008, 86: 8-160.

25. Brozek J.L., Bousquet J., Baena-Cagnani C.E. i wsp.: Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010, 3: 466–476.

26. Corcostegui R., et al., Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and vitro antihistaminic activity. Drugs RD, 2005. 6(6):p.371-384.

27. Corcostegui R., et al., In vivo pharmacological characterization of bilastine, a potent and selective histamine H1 receptor antagonist. RD, 2006. 7(4):p.219-231.

28. Jauregizar N., et al., Pharmacokinetic-pharmacodynamic modeling of the antihistaminic (H1) effect of bilastine. Clin Pharamacokinet, 2009. 48(8):p.543-544.

29. Ciprandi G., Cosentino C., Milanese M. i wsp.: Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy 2001 Nov, 56 (11): 1068–1070.

30. Wilson A.M., Haggart K., Sims E.J., Lipworth B.J.: Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 2002 Oct, 32 (10): 1504–1509.

31. Horak F., Stubner P., Zieglmayer R. i wsp.: Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001 May, 125 (1): 73–79.

32. Schenkel E., Corren J., Murray J.J.: Efficacy of oncedaily desloratadine/pseudoephedrine for relief of nasal congestion. Allergy Asthma Proc 2002 Sep–Oct, 23 (5): 325–330.

33. Nayak A.S., Schenkel E.: Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001 Nov, 56 (11): 1077–1080.

34. Berger W.E., Schenkel E.J., Mansfield L.E., Desloratadine Study Group: Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002 Nov, 89 (5): 485–491.

35. Horak F., Stubner P., Zieglmeyer R., Harris A.G.: Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy 2003 Jun, 58 (6): 481–485.

36. Tworek D., Kuna P., i wsp.: Nowoczesne leczenie alergicznego nieżytu nosa lekami przeciw-histaminowymi. Terapia: 2011: R. 19, nr 4, s. 95-97.

37. Noon L: Prophylactic inoculation against hay fever. Lancet 1911, 1572-1573.